Esomeprazole

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postoperative Bariatric Surgery

Conditions

Postoperative Bariatric Surgery

Trial Timeline

Nov 1, 2005 → Aug 1, 2006

NCT ID

NCT00608712

About Esomeprazole

Esomeprazole is a approved stage product being developed by AstraZeneca for Postoperative Bariatric Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT00608712. Target conditions include Postoperative Bariatric Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01370538	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT01370525	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT00474019	Phase 1	Completed	Oct 1, 2007	Oct 1, 2009	Pharmacokinetics
NCT00427635	Phase 3	Completed	Oct 1, 2006	Apr 1, 2009	GERD
NCT00384592	Approved	Completed	Sep 1, 2006	May 1, 2007	Gastro-Oesophageal Reflux Disease
NCT00318968	Approved	Completed	May 1, 2006	Nov 1, 2007	GERD
NCT00608712	Approved	Completed	Nov 1, 2005	Aug 1, 2006	Postoperative Bariatric Surgery
NCT00251979	Phase 3	Completed	Oct 1, 2005	Dec 1, 2007	Gastrointestinal Hemorrhage
NCT00392002	Approved	Completed	Oct 1, 2005	May 1, 2007	Gastroesophageal Reflux
NCT00242736	Approved	Completed	Oct 1, 2005	Jan 1, 2006	GERD
NCT00291746	Approved	Completed	Sep 1, 2005	Nov 1, 2006	Gastroesophageal Reflux
NCT00206440	Phase 3	Terminated	Aug 1, 2005	Feb 1, 2012	Nausea
NCT00243724	Phase 3	Completed	Apr 1, 2005	Jun 1, 2007	Gastroesophageal Reflux
NCT00524251	Pre-clinical	Completed	Jun 1, 2004	Mar 1, 2008	GERD
NCT00251966	Phase 3	Completed	May 1, 2004	Sep 1, 2005	Gastroesophageal Reflux
NCT00251901	Phase 3	Completed	May 1, 2004	Jul 1, 2005	Chest Pain
NCT00120315	Approved	Completed	Dec 1, 2003	Mar 1, 2007	Dyspepsia
NCT00574925	Approved	Completed	Nov 1, 2003	Oct 1, 2007	Gastroesophageal Reflux Disease (GERD)
NCT00222131	Phase 2	Completed	Oct 1, 2003	Jan 1, 2008	Indigestion
NCT00318084	Approved	Completed	Jan 1, 2003	—	GERD

Competing Products

20 competing products in Postoperative Bariatric Surgery

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 2	52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IV	Eisai	Approved	85
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	52
Ondansetron + Palonosetron	Eisai	Phase 2	52
AQUAVAN (fospropofol disodium; GPI 15715 )	Eisai	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2/3	65
Levofloxacin Ophthalmic + Cefuroxime	Santen Pharmaceutical	Phase 1/2	41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution	Santen Pharmaceutical	Phase 1/2	41
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	33
SHR0410 Injection + SHR0410 Injection + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
SHR8554 Injection	Jiangsu Hengrui Medicine	Phase 1	33
deep neuromuscular block	Merck	Pre-clinical	23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo	Merck	Phase 2	52
MK0966, rofecoxib + Comparator: valdecoxib	Merck	Phase 3	77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, Placebo	Merck	Approved	85
MK0719	Merck	Phase 2	52
Sugammadex + Neostigmine	Merck	Approved	85
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	77
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved